MLXIPL and fatty liver disease: Pharmacological inhibition of ketohexokinase, the first step in the metabolism of fructose, lowers liver ChREBP, hyperinsulinemia, hypertriglyceridemia, and hepatic steatosis in mice fed a Western diet (115, 116) while also reducing liver steatosis, serum uric acid, and high-sensitivity CRP in people with MASLD (117).